# Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

> **NCT06117878** · EARLY_PHASE1 · UNKNOWN · sponsor: **Base Therapeutics (Shanghai) Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Osteosarcoma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** NK510
- **DRUG:** NK510

## Key facts

- **NCT ID:** NCT06117878
- **Lead sponsor:** Base Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06117878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06117878, "Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06117878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*